Maruyama Dai, Watanabe Takashi, Beppu Yasuo, Kobayashi Yukio, Kim Sung-Won, Tanimoto Kazuki, Makimoto Atsushi, Kagami Yoshikazu, Terauchi Takashi, Matsuno Yoshihiro, Tobinai Kensei
Hematology and Stem Cell Transplantation Division, Cancer Center Hospital, Tokyo, Japan.
Jpn J Clin Oncol. 2007 Mar;37(3):216-23. doi: 10.1093/jjco/hym007.
The incidence of primary bone lymphoma (PBL) is so rare that many of its aspects remain unknown. A number of studies have been reported from Western countries, but only a few reports are available from Asia.
We retrospectively analyzed 28 consecutive patients diagnosed with PBL initially treated at our hospital between 1995 and 2004. All patients underwent chemotherapy with half receiving radiotherapy as their initial treatment. A log-rank test was used in a univariate analysis to identify factors affecting overall survival.
Fifteen (54%) patients were male and 13 (46%) female with a median age of 47 (range: 5-81). Although 19 (68%) patients had diffuse large B-cell lymphoma (DLBCL), other histopathological subtypes (three B-lymphoblastic lymphoma, two anaplastic large cell lymphoma, two indolent B-cell lymphoma, one NK/T-cell lymphoma (NTCL) and one Hodgkin lymphoma) were also included. The pelvis was the most frequently involved site (54%). While 68% of patients had stage IV disease, none of them showed bone marrow involvement at their initial diagnosis. Despite 61% high intermediate-risk and high-risk patients based on the International Prognostic Index, the estimated 3-year overall and progression-free survival rates were 84% and 77%, respectively. Only 'histopathological subtype (immunoblastic variant of DLBCL or NTCL versus others)' and 'response to initial treatment (progression versus remission)' were factors significantly affecting overall survival.
Although the total number of patients was relatively small, the detailed clinical data analyses presented here revealed several new characteristics of PBL and some aspects that may be unique to Japanese patients.
原发性骨淋巴瘤(PBL)的发病率极低,其许多方面仍不为人所知。西方国家已有多项相关研究报道,但亚洲地区仅有少数报告。
我们回顾性分析了1995年至2004年间在我院初治的28例连续诊断为PBL的患者。所有患者均接受化疗,其中一半患者初始治疗时接受放疗。采用对数秩检验进行单因素分析,以确定影响总生存期的因素。
15例(54%)患者为男性,13例(46%)为女性,中位年龄47岁(范围:5 - 81岁)。虽然19例(68%)患者为弥漫性大B细胞淋巴瘤(DLBCL),但也包括其他组织病理学亚型(3例B淋巴母细胞淋巴瘤、2例间变性大细胞淋巴瘤、2例惰性B细胞淋巴瘤、1例NK/T细胞淋巴瘤(NTCL)和1例霍奇金淋巴瘤)。骨盆是最常受累部位(54%)。68% 的患者为IV期疾病,但初诊时均无骨髓受累。尽管根据国际预后指数,61% 为高中危和高危患者,但估计3年总生存率和无进展生存率分别为84% 和77%。仅“组织病理学亚型(DLBCL免疫母细胞变异型或NTCL与其他亚型)”和“对初始治疗的反应(进展与缓解)”是显著影响总生存期的因素。
尽管患者总数相对较少,但本文所呈现的详细临床数据分析揭示了PBL的几个新特征以及一些可能为日本患者所特有的方面。